Made available in DSpace on 2014-12-17T14:25:21Z (GMT). No. of bitstreams: 1
AlyneSP_DISSERT.pdf: 2677800 bytes, checksum: ae0cc2c34a761b6f5adc64dba8b50ed8 (MD5)
Previous issue date: 2013-07-01 / Alpha-lipoic acid (ALA) is a potent antioxidant with favourable anti-inflammatory, metabolic and endothelial effects, and has been widely investigated due to its potential against cardiovascular risk factors. This study aimed to evaluate the effect of oral ALA supplementation on oxidative stress biomarkers, inflammation and cardiovascular risk factors in patients with hypertension. This is a double-blind placebo-controlled randomized clinical trial, where the intervention was evaluated prospectively comparing results in both groups. The sample consisted of 64 hypertensive patients who were randomly distributed into ALA group (n = 32), receiving 600 mg / day ALA for twelve weeks and control group (n = 32), receiving placebo for the same period. The following parameters were evaluated before and after intervention: lipid peroxidation, content of reduced glutathione (GSH), enzymatic activities of glutathione peroxidase (GPx) and superoxide dismustase, ultrasensitive C-reactive protein (hs-CRP), triglycerides, total cholesterol and fractions, fasting glucose and anthropometric indicators. There was a statistically significant reduction (p <0.05) in serum concentrations of total cholesterol, very low density lipoprotein (VLDL), high density lipoprotein (HDL), triglycerides and blood glucose. There was a reduction in body weight and waist, abdominal and hip circumferences in the group that received ALA. In addition, there was a statistically significant increase (p <0.05) in the contents of reduced glutathione (GSH) and glutathione peroxidase (GPx) in the group receiving ALA. Oral administration of ALA appears to be a valuable adjuvant therapy, which may contribute to decrease the damage caused by oxidative stress and other risk factors associated with the atherosclerotic process / O ?cido alfa-lip?ico (AAL) ? um potente antioxidante, com favor?veis efeitos antiinflamat?rios, metab?licos e endoteliais, assim vem sendo intensamente investigado no combate aos fatores de risco cardiovascular. O estudo teve como objetivo avaliar o efeito da suplementa??o oral do AAL sobre biomarcadores de estresse oxidativo, inflama??o e fatores de risco cardiovascular em portadores de hipertens?o. Trata-se de um estudo cl?nico randomizado, duplo-cego e controlado com placebo, no qual a interven??o foi avaliada prospectivamente, comparando os resultados nos dois grupos. A amostra foi constitu?da por 64 indiv?duos hipertensos que foram distribu?dos aleatoriamente em grupo AAL (n=32), que recebeu 600 mg/dia de AAL por doze semanas e grupo controle (n=32), que recebeu o placebo pelo mesmo per?odo. Foram avaliados antes e depois da interven??o: subst?ncias reativas ao ?cido tiobarbit?rico (SRAT), conte?do da glutationa reduzida (GSH); atividades enzim?ticas da glutationa peroxidase (GPx) e da super?xido dismustase; prote?na C reativa (PCR-us); triglicer?deos, colesterol total e fra??es; glicemia de jejum; e indicadores antropom?tricos. Observou-se uma redu??o estatisticamente significativa (p < 0.05) nas concentra??es s?ricas de colesterol total, lipoprote?na de muita baixa densidade (VLDL), lipoprote?na de alta densidade (HDL), triglicer?deos e glicose. No grupo AAL Tamb?m houveram redu??es do peso corporal e das circunfer?ncias abdominais, da cintura e do quadril. Ainda, observou-se um aumento estatisticamente significativo (p < 0.05) do conteudo de glutationa reduzida (GSH) e da atividade da glutationa peroxidase (GPx) no grupo que recebeu o AAL. A administra??o oral do AAL mostrou-se como um valioso adjuvante terap?utico, que pode contribuir com a diminui??o dos danos causados pelo estresse oxidativo e outros fatores de risco cardiovascular que est?o associados com o processo ateroscler?tico / 2019-11-09
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/13865 |
| Date | 01 July 2013 |
| Creators | Portela, Alyne da Silva |
| Contributors | CPF:20054548420, http://lattes.cnpq.br/0321740024191482, Rebecchi, Ivanise Marina Moretti, CPF:08777147898, http://lattes.cnpq.br/7308186244207080, Lima, Severina Carla Vieira Cunha, CPF:47473487434, http://lattes.cnpq.br/8818927353248941, Campa, Ana, CPF:01368803806, http://lattes.cnpq.br/1891164895185158, Rodriguez, Jorge Alberto Lopez, CPF:27657779420, http://lattes.cnpq.br/6940701204545519, Almeida, Maria das Gra?as |
| Publisher | Universidade Federal do Rio Grande do Norte, Programa de P?s-Gradua??o em Desenvolvimento e Inova??o Tecnol?gica em Medicamentos, UFRN, BR, Inova??o Tecnol?gica em Medicamentos |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/doctoralThesis |
| Format | application/pdf |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/embargoedAccess |
Page generated in 0.0032 seconds